Theratechnologies Secures Canadian Rights for Ionis RNA Medicines: A Boost to Growth and Innovation.

Theratechnologies Inc. has secured Canadian rights to two investigational RNA-targeted medicines from Ionis Pharmaceuticals: olezarsen for familial chylomicronemia syndrome and severe hypertriglyceridemia, and donidalorsen for hereditary angioedema. This collaboration strengthens Theratechnologies' commitment to growth and innovation in North America and provides new treatment options for Canadian patients. The company operates in the pharmaceutical industry and is focused on providing innovative treatments for unmet medical needs in Canada.

The pharmaceutical industry landscape in Canada is set to experience a significant transformation with Theratechnologies Inc.'s recent announcement of an exclusive licensing agreement with Ionis Pharmaceuticals, Inc. [1] This collaboration grants Theratechnologies the Canadian rights to commercialize two investigational RNA-targeted medicines: olezarsen and donidalorsen.

Olezarsen, an investigational therapy designed to lower apoC-III levels, is being evaluated for the treatment of familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG). [1] The condition, characterized by abnormally high levels of triglycerides in the blood, affects approximately one in every 1 million people worldwide. [2] FCS and sHTG patients are at risk of pancreatitis, which can be life-threatening. By targeting the underlying cause of these conditions, olezarsen has the potential to provide a significant improvement in patients' quality of life.

Donidalorsen, another investigational RNA-targeted medicine, is being evaluated for the treatment of hereditary angioedema (HAE), a rare and potentially life-threatening genetic disorder. [1] HAE affects approximately 1 in 50,000 to 1 in 100,000 people worldwide. [3] The condition is characterized by recurrent episodes of swelling in various parts of the body, including the face, hands, feet, genitals, and gastrointestinal tract. These episodes can lead to significant pain, discomfort, and even death in severe cases. Donidalorsen, by targeting the underlying genetic cause of HAE, has the potential to provide a much-needed treatment option for patients suffering from this debilitating condition.

The addition of these investigational RNA-targeted medicines builds upon Theratechnologies' foundational HIV portfolio and strengthens the company's commitment to growth and innovation in North America. Submissions to Health Canada for the approval of olezarsen and donidalorsen are planned for 2025. [1]

This collaboration is a testament to Theratechnologies' team's capabilities to advance innovation across North America and reaffirms the company's commitment to being a commercially focused organization that delivers sustained top- and bottom-line growth and value for shareholders.

References:
[1] Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada. (2024, December 4). Retrieved December 5, 2024, from https://www.globenewswire.com/news-release/2024/12/04/2991373/0/en/Theratechnologies-Announces-Exclusive-Licensing-Agreement-with-Ionis-to-Commercialize-Olezarsen-and-Donidalorsen-in-Canada.html
[2] Familial Chylomicronemia Syndrome. (n.d.). Retrieved December 5, 2024, from https://www.niddk.nih.gov/health-information/endocrine-diseases/familial-chylomicronemia-syndrome
[3] Hereditary Angioedema. (n.d.). Retrieved December 5, 2024, from https://www.niddk.nih.gov/health-information/blood/hereditary-angioedema